In this study, treatment of Tregs with Rapa increased autophagy levels, after which the function of Tregs returned to nearly normal levels, suggesting that the mTOR inhibitor Rapa can be used to treat patients with MG, but further studies are needed to determine the underlying mechanisms. This evidence concerns the gene TRERF1 and myasthenia gravis.